Table 1  Comparison of pelvic node-positive patients in the CaRE-1 and UKE cohorts.

	Status unknown	pelvic N+, UKE n = 6	pelvic N+, CaRE-1 n = 14	Total n = 20
LN: lymph node; LAE: lymphadenectomy; No.: number; OS: overall survival; PFS: progression-free survival; pt.: patient * TNM classification, version 6
Patient age, median (range)		56.5 (37.0 – 70.0)	71.5 (31.5 – 82.8)	64.0 (34.3 – 74.4)
Tumor stage
pT1b		3	3	6 (80%)
pT2		1	6	7 (35%)
pT3/4*		1	0	1 (2%)
unknown		1	5	6 (30%)
Node status (inguinal)
pN−		0	0	0
pN+		6	14	20 (100%)
No. of affected inguinal LNs, median (range)	4	4.5 (2.0 – 9.0)	7 (1.0 – 30.0)	5.8 (1.5 – 19.5)
Maximum diameter of inguinal LN metastasis in mm, median (range)	5	45.0 (23.0 – 54.0)	42.5 (12.0 – 50.0)	43.75 (17.5 – 52)
No. of affected pelvic LNs, median (range)		2.5 (1.0 – 8.0)	2.5 (1.0 – 12.0)	2.5 (1.0 – 10.0)
No. of resected LNs per pt., median (range)		19 (12 – 24)	15 (6 – 36)	17 (9 – 30)
No. of resected pelvic LNs per pt., median (range)		16 (6 – 27)	10 (1 – 28)	13 (3 – 28)
Depth of invasion in mm, median (range)	9	11.5 (7.0 – 16.0)	5.3 (5.0 – 6.0)	8.4 (6.0 – 11.0)
Grading
G 1		0	0	0
G 2		4	4	8 (40%)
G 3		2	10	12 (60%)
Vulvar surgery
partial vulvectomy		3	3	6 (30%)
complete vulvectomy		1	10	11 (55%)
no surgery/unknown		2	1	3 (15%)
Resection margin in mm, median (range)	11	2.4 (0.9 – 4.0)	3.0 (2.0 – 4.0)	2.7 (1.5 – 4.0)
Inguinofemoral LAE		6	14	20 (100%)
unilateral		1 (16.7%)	n. a.	n. a.
bilateral		5 (83.3%)	n. a.	n. a.
Pelvic LAE		6	14	20 (100%)
unilateral		2 (33.3%)	n. a.	n. a.
bilateral		4 (66.7%)	n. a.	n. a.
Radiotherapy
radiotherapy	4	1 (16.7%)	10	11 (55%)
radiochemotherapy (RCTX)		4 (66.7%)	n. a.	n. a.
neoadjuvant RCTX		1 (16.7%)	n. a.	n. a.
Areas treated with radiotherapy	5
groin ± vulva		0	2	2 (10%)
groin and pelvis ± vulva		6	6	12 (60%)
pelvis ± vulva		0	1	1 (2%)
Median PFS (months)	1	9.9	12.5	11.7
Median OS (months)	1	31.1	30.8	31.0